4D Molecular Therapeutics (FDMT) Long-Term Investments (2021 - 2026)

4D Molecular Therapeutics (FDMT) has 6 years of Long-Term Investments data on file, last reported at $66.7 million in Q1 2026.

• Long-Term Investments for Q1 2026 came in at $66.7 million, down 51.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $66.7 million (down 51.29% YoY), and the FY2025 annual result was $111.4 million, up 38.22% from the prior year.
• Long-Term Investments slipped to $66.7 million in Q1 2026 per FDMT's latest filing, from $111.4 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $137.0 million in Q1 2025 and troughed at $1.4 million in Q1 2023.
• A 5-year average of $55.4 million and a median of $48.8 million in 2024 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2023 and 2024: Long-Term Investments plunged 97.09% in 2023, then soared 4379.86% in 2024.
• A 5-year view of Long-Term Investments shows it stood at $4.9 million in 2022, then surged by 123.19% to $11.0 million in 2023, then soared by 635.65% to $80.6 million in 2024, then soared by 38.22% to $111.4 million in 2025, then plunged by 40.08% to $66.7 million in 2026.
• Business Quant data shows FDMT's Long-Term Investments at $66.7 million in Q1 2026, $111.4 million in Q4 2025, and $67.2 million in Q3 2025.